|
- 2019
Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor ReceptorDOI: 10.14740/wjon1184 Keywords: Gustave Roussy Immune Score, Non-small cell lung cancer, Adenocarcinoma, Squamous cell carcinoma, Neutrophil-to-lymphocyte ratio, Serum albumin, Lactate dehydrogenase, Epidermal growth factor receptor Abstract: The Gustave Roussy Immune Score (GRIm-Score) was developed based on the Royal Marsden Hospital (RMH) prognostic score for the purpose of a better patient selection for immunotherapy phase I trials. This scoring system is simply calculated by neutrophil-to-lymphocyte ratio, lactate dehydrogenase (LDH), and serum albumin concentration. The aim of our study was to determine whether GRIm-Score is a practically useful prognostic biomarker for advanced non-small cell lung cancer (NSCLC) patients treated with cytotoxic chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
|